Video Experimental Relacionado
Updated: Jul 30, 2026
12:06
Metabolic Glycoengineering of Sialic Acid Using N-acyl-modified Mannosamines
Published on: November 25, 2017
Inhibidores eficientes de la sialyltransferasa basados en glucósidos de N-acetilglucosamina
Ralf Schwörer1, Richard R Schmidt
1Fachbereich Chemie, Universität Konstanz, Fach M 725, D-78457 Konstanz, Germany.
Journal of the American Chemical Society
|February 21, 2002
Resumen
Los investigadores sintetizaron nuevos derivados de la N-acetilglucosamina que imitan el ácido 2,3-dehidroneuraminico. Estos compuestos inhiben eficazmente la alfa-sialyltransferasa, mostrando potencial como agentes terapéuticos.
Área de la Ciencia:
- Química medicinal Química medicinal es el campo de la química medicinal.
- La glucoquímica es la química de la glucosa.
- La inhibición de la enzima inhibición de la enzima.
Sus antecedentes:
- La alfa ((2-6) -sialiltransferasa juega un papel crucial en los procesos celulares.
- El desarrollo de inhibidores específicos para esta enzima es importante para aplicaciones terapéuticas.
Objetivo del estudio:
- Para sintetizar nuevos análogos del estado de transición del ácido monofosfato-N-acetilneuramínico de citidina.
- Para evaluar el potencial inhibidor de estos análogos contra la alfa-sialyltransferasa.
Principales métodos:
- Síntesis química comenzando desde la D-glucosamina.
- Generación de aldehído insaturado que imita el ácido 2,3-dehidroneuraminico.
- Adición de fosfonatos y adherencia de residuos de CMP para formar análogos protegidos.
Principales resultados:
- Sintetizó análogos de estado de transición protegidos (14a,b) y sus formas desprotegidas (1ah,l, 1bh,l).
- Se logró una excelente inhibición de la alfa ((2-6) -sialiltransferasa del hígado de rata con los compuestos 1ah,l y 1bh,l.
- Derivados de dieno generados (E) -/Z) - 2a,b, que también mostraron propiedades inhibidoras.
Conclusiones:
- Los derivados sintetizados de la N-acetilglucosamina son potentes inhibidores de la alfa(2-6)-sialiltransferasa.
- Estos compuestos representan perspectivas prometedoras para el desarrollo de nuevas estrategias terapéuticas dirigidas a la actividad de la sialyltransferasa.
Videos de Conceptos Relacionados
02:30siRNA - Small Interfering RNAs
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
01:24Oligosaccharide Assembly
Protein glycosylation starts in the ER lumen and continues in the Golgi apparatus. Glycosyltransferases catalyze the addition of sugar molecules or glycosylation of proteins. Usually, these enzymes add sugars to the hydroxyl groups of selected serine or threonine residues to form O-linked glycans or the amino groups of asparagine residues to form N-linked glycans. Different positions on the same polypeptide chain can contain differently linked glycans.
Multiple sugar molecules that may or may...
Multiple sugar molecules that may or may...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...